FDA Expands Indication for Xtandi to Treat Metastatic Castration-Sensitive Prostate Cancer – Renal and Urology News

The primary end point was radiographic progression-free survival (rPFS), defined as the time from randomization to radiographic disease progression at any time or death within 24 weeks after drug discontinuation.

Read the full article here

Related Articles